U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H16FIN4OS
Molecular Weight 482.314
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of WX-554

SMILES

NCC1CN(C1)C(=O)C2=C(NC3=C(F)C=C(I)C=C3)SC4=C2C=CC=N4

InChI

InChIKey=DJIBEZXMCYNIQJ-UHFFFAOYSA-N
InChI=1S/C18H16FIN4OS/c19-13-6-11(20)3-4-14(13)23-17-15(12-2-1-5-22-16(12)26-17)18(25)24-8-10(7-21)9-24/h1-6,10,23H,7-9,21H2

HIDE SMILES / InChI

Molecular Formula C18H16FIN4OS
Molecular Weight 482.314
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Wed Apr 02 19:12:30 GMT 2025
Edited
by admin
on Wed Apr 02 19:12:30 GMT 2025
Record UNII
36TRH66AA6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
WX-554
Code English
Methanone, [3-(aminomethyl)-1-azetidinyl][2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridin-3-yl]-
Preferred Name English
[3-(Aminomethyl)-1-azetidinyl][2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridin-3-yl]methanone
Systematic Name English
Code System Code Type Description
CAS
945529-91-9
Created by admin on Wed Apr 02 19:12:30 GMT 2025 , Edited by admin on Wed Apr 02 19:12:30 GMT 2025
PRIMARY
NCI_THESAURUS
C101532
Created by admin on Wed Apr 02 19:12:30 GMT 2025 , Edited by admin on Wed Apr 02 19:12:30 GMT 2025
PRIMARY
FDA UNII
36TRH66AA6
Created by admin on Wed Apr 02 19:12:30 GMT 2025 , Edited by admin on Wed Apr 02 19:12:30 GMT 2025
PRIMARY
PUBCHEM
68915728
Created by admin on Wed Apr 02 19:12:30 GMT 2025 , Edited by admin on Wed Apr 02 19:12:30 GMT 2025
PRIMARY
SMS_ID
300000054799
Created by admin on Wed Apr 02 19:12:30 GMT 2025 , Edited by admin on Wed Apr 02 19:12:30 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY
Patients with treatment-refractory, advanced solid tumours.